Annual Reports

 
Quarterly Reports

  • 10-Q (Feb 7, 2011)
  • 10-Q (Nov 5, 2010)
  • 10-Q (Aug 5, 2010)
  • 10-Q (Feb 5, 2010)
  • 10-Q (Nov 6, 2009)
  • 10-Q (Aug 10, 2009)

 
8-K

 
Other

Matrixx Initiatives 10-Q 2010

Documents found in this filing:

  1. 10-Q
  2. Ex-31.1
  3. Ex-32.1
  4. Ex-32.1
e10vq
Table of Contents

 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
 
Form 10-Q
(Mark One)
     
þ   Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
For the quarter ended June 30, 2010
or
     
o   Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Commission File number 001-31404
Matrixx Initiatives, Inc.
(Name of registrant as specified in its charter)
     
Delaware   87-0482806
(State or other jurisdiction   (I.R.S. Employer
of incorporation or organization)   Identification Number)
8515 E. Anderson Drive
Scottsdale, AZ 85255

(Address of principal executive offices)
(602) 385-8888
(Issuer’s telephone number)
     Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES þ NO o
     Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes o No o
     Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
             
Large accelerated filer o   Accelerated filer þ   Non-accelerated filer o   Smaller reporting company o
        (Do not check if a smaller reporting company)    
Indicate by check mark whether the registrant is a shell company (as defined in Exchange Act Rule 12b-2). YES o NO þ
There were 9,399,987 shares of the registrant’s common stock, $.001 par value, outstanding as of July 30, 2010.
 
 

 


 

MATRIXX INITIATIVES, INC.
FORM 10-Q
INDEX
         
    Page  
       
 
       
    3  
 
       
    4  
 
       
    5  
 
       
    6  
 
       
    16  
 
       
    27  
 
       
    27  
 
       
       
 
       
    27  
 
       
    27  
 
       
    27  
 
       
    28  
 
       
    29  
 EX-31.1
 EX-32.1
Unless otherwise indicated in this quarterly report, “Matrixx,” “us,” “we,” “our”, “the Company” and similar terms refer to Matrixx Initiatives, Inc. and its subsidiaries. “Zicam” is a registered trademark of our subsidiary, Zicam, LLC, and the Matrixx name and logo are trademarks of the Company.

2


Table of Contents

MATRIXX INITIATIVES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
                 
    June 30,   March 31,
    2010   2010
     
ASSETS
               
 
               
Current Assets:
               
Cash and cash equivalents
  $ 28,267,218     $ 26,482,499  
Certificates of deposit
          3,736,525  
Accounts receivable:
               
Trade, net of allowance for doubtful accounts of $168,139 and $169,720
    1,617,155       5,386,044  
Insurance receivable
    2,204,000        
Inventories
    7,007,681       6,166,809  
Prepaid expenses
    1,269,465       2,230,116  
Interest receivable
    820       3,443  
Income tax receivable
    7,220,293       5,661,554  
Current deferred tax asset
    5,265,820       5,071,475  
     
Total Current Assets
    52,852,452       54,738,465  
     
 
               
Property and Equipment, at cost:
               
Office furniture and computer equipment
    1,575,947       1,722,176  
Machine tooling and manufacturing equipment
    4,415,352       4,415,352  
Laboratory furniture and equipment
    370,355       486,459  
Leasehold improvements
    415,452       562,738  
     
 
    6,777,106       7,186,725  
Less accumulated depreciation
    (3,808,981 )     (3,865,302 )
     
 
               
Net Property and Equipment
    2,968,125       3,321,423  
     
 
               
Other Assets:
               
Deposits
    636,924       636,924  
Other assets
    40,043       40,043  
Patents, net of accumulated amortization of $330,260 and $311,209
    774,756       793,807  
Non-current deferred tax asset
    1,845,871       1,934,686  
     
 
               
Total Other Assets
    3,297,594       3,405,460  
     
 
               
Total Assets
  $ 59,118,171     $ 61,465,348  
     
 
LIABILITIES AND STOCKHOLDERS’ EQUITY
               
 
               
Current Liabilities:
               
Accounts payable
  $ 2,472,919     $ 1,007,886  
Accrued expenses
    5,233,572       7,026,708  
Sales commissions
    79,857       188,433  
Sales returns and allowances
    1,847,338       1,420,600  
Legal liability
    740,000       740,000  
     
 
               
Total Current Liabilities
    10,373,686       10,383,627  
     
 
               
Total Liabilities
    10,373,686       10,383,627  
 
               
Commitments and Contingencies
               
 
               
Stockholders’ Equity:
               
Preferred stock: $.001 par value, 2,000,000 shares authorized, none issued or outstanding
           
Common stock: $.001 par value, 30,000,000 shares authorized, 9,399,987 and 9,455,620 shares issued and outstanding
    9,400       9,455  
Additional paid-in capital
    38,753,271       38,657,444  
Retained earnings
    9,981,814       12,414,822  
     
Total Stockholders’ Equity
    48,744,485       51,081,721  
     
Total Liabilities and Stockholders’ Equity
  $ 59,118,171     $ 61,465,348  
     
The accompanying notes are an integral part of these consolidated financial statements.

3


Table of Contents

MATRIXX INITIATIVES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE THREE MONTHS ENDED JUNE 30, 2010 AND 2009
(Unaudited)
                 
    2010   2009
     
Net sales
  $ 3,207,398     $ 6,916,237  
Cost of sales
    1,332,578       2,793,062  
     
 
               
Gross Profit
    1,874,820       4,123,175  
 
               
Selling, general and administrative expenses
    5,313,898       16,488,637  
Research and development
    530,228       934,393  
Goodwill impairment
          15,039,836  
Asset impairments
          8,827,322  
     
 
               
Loss From Operations
    (3,969,306 )     (37,167,013 )
 
               
Interest and other income
    16,398       47,280  
     
 
               
Loss Before Income Taxes
    (3,952,908 )     (37,119,733 )
 
               
Income taxes
    (1,519,900 )     (14,287,481 )
     
 
               
Net Loss
  $ (2,433,008 )   $ (22,832,252 )
     
 
               
Net Loss Per Share of Common Stock:
               
Basic and Diluted:
               
Weighted Average Number of Common Shares Outstanding
    9,287,580       9,169,829  
Net Loss Per Share of Common Stock
  $ (0.26 )   $ (2.49 )
The accompanying notes are an integral part of these consolidated financial statements.

4


Table of Contents

MATRIXX INITIATIVES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE THREE MONTHS ENDED JUNE 30, 2010 AND 2009
(Unaudited)
                 
    2010   2009
     
Cash Flows From Operating Activities
               
Net loss
  $ (2,433,008 )   $ (22,832,252 )
Adjustments to reconcile net loss to net cash used by operating activities:
               
Depreciation
    370,664       256,016  
Amortization
    19,051       37,621  
Deferred income taxes
    (105,530 )     (14,597,763 )
Common stock issued for compensation
    249,592       1,015,979  
Asset impairments and abandonments
          24,287,130  
Changes in assets and liabilities:
               
Accounts receivable
    3,768,889       8,511,844  
Insurance receivable
    (2,204,000 )     (49,486 )
Interest and other receivables
    2,623       (57,850 )
Income tax receivable
    (1,558,739 )     (265,479 )
Inventories
    (840,872 )     (2,744,968 )
Prepaid expenses and other
    960,651       372,806  
Accounts payable
    1,465,033       840,699  
Accrued expenses
    (1,901,712 )     4,313,905  
Legal liability
          (20,000 )
Sales returns and allowances
    426,738       399,262  
     
 
               
Net Cash Used By Operating Activities
    (1,780,620 )     (532,536 )
     
 
               
Cash Flows From Investing Activities
               
Purchases of certificates of deposit
          (3,736,525 )
Maturities of certificates of deposit
    3,736,525       3,621,548  
Capital expenditures
    (17,366 )     (22,612 )
Deposits and other
          (2,232,250 )
     
 
               
Net Cash Provided (Used) By Investing Activities
    3,719,159       (2,369,839 )
     
 
               
Cash Flows From Financing Activities:
               
Issuance of common stock
          1,362,219  
Purchase of treasury stock
    (153,820 )     (1,187,906 )
     
 
               
Net Cash Provided (Used) By Financing Activities
    (153,820 )     174,313  
     
 
               
Net Increase (Decrease) in Cash and Cash Equivalents
    1,784,719       (2,728,062 )
 
               
Cash and Cash Equivalents at Beginning of Period
    26,482,499       25,144,088  
     
 
               
Cash and Cash Equivalents at End of Period
  $ 28,267,218     $ 22,416,026  
     
Supplemental Disclosure of Cash Flow Information:
               
Cash paid for income taxes
  $     $ 8,000  
Supplemental Disclosure of Noncash Financing Activities:
               
Retirement of treasury stock
  $ 153,820     $ 1,187,906  
The accompanying notes are an integral part of these consolidated financial statements.

5


Table of Contents

MATRIXX INITIATIVES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
1. Description of Business and Basis of Presentation
     Matrixx Initiatives, Inc. markets and sells over the counter products with an emphasis on those that utilize unique or novel delivery systems. Through our subsidiaries, we market and sell products under the Zicam® brand.
     The accompanying condensed consolidated balance sheet as of March 31, 2010, which has been derived from audited consolidated financial statements, and the unaudited interim condensed consolidated financial statements of Matrixx Initiatives, Inc. as of and for the three months ended June 30, 2010 have been prepared in accordance with the rules prescribed for filing condensed interim financial statements and, accordingly, do not include all disclosures that may be necessary for complete financial statements prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). The disclosures presented are sufficient, in management’s opinion, to make the interim information presented not misleading. All adjustments, consisting of normal recurring adjustments that are necessary so as to make the interim information not misleading, have been made. All references made in this Report to “Note” or “Notes” refer to these Notes to the Condensed Consolidated Financial Statements (“Financial Statements”). Results of operations for the three months ended June 30, 2010 are not necessarily indicative of results of operations that may be expected for the fiscal year ending March 31, 2011. The products we market are seasonal in nature. We record sales when products are shipped from our warehouse facilities to customers. Generally, the Company realizes fluctuations in sales volume as retailers stock our products and order displays to prepare for the cough and cold season, which usually runs from October through March. Consumer purchases of our products at retail are highest during the cough and cold season. It is recommended that this financial information be read in conjunction with the complete financial statements included in Matrixx’s Annual Report on Form 10-K for the fiscal year ended March 31, 2010 previously filed with the Securities and Exchange Commission (“SEC”).
2. Recently Issued Authoritative Guidance
     In April 2010 we adopted the FASB’s guidance on the Consolidation Topic of the Codification (ASC Topic 810-10). This updated guidance requires an enterprise to determine whether its variable interest or interests give it a controlling financial interest in a variable interest entity; to require ongoing reassessments of whether an enterprise is the primary beneficiary of a variable interest entity; to eliminate the quantitative approach previously required for determining the primary beneficiary of a variable interest entity; to add an additional reconsideration event for determining whether an entity is a variable interest entity when any changes in facts and circumstances occur such that holders of the equity investment at risk, as a group, lose the power from voting rights or similar rights of those investments to direct the activities of the entity that most significantly impact the entity’s economic performance; and to require enhanced disclosures that will provide users of financial statements with more transparent information about an enterprise’s involvement in a variable interest entity. The adoption of this guidance did not impact our Financial Statements.
     In October 2009, the FASB issued Accounting Standards Update (“ASU”) No. 2009-13, Revenue Recognition (ASC Topic 605) — Multiple-Deliverable Revenue Arrangements, a consensus of the FASB Emerging Issues Task Force. This guidance modifies the fair value requirements of ASC subtopic 605-25 Revenue Recognition-Multiple Element Arrangements by allowing the use of the “best estimate of selling price” in addition to VSOE and VOE (now referred to as TPE standing for third-party evidence) for determining the selling price of a deliverable. A vendor is now required to use its best estimate of the selling price when VSOE or TPE of the selling price cannot be determined. In addition, the residual method of allocating arrangement consideration is no longer permitted. This update requires expanded qualitative and quantitative disclosures and is effective for fiscal years beginning on or after June 15, 2010. This update may be applied either prospectively from the beginning of the fiscal year for new or materially modified arrangements or retrospectively. The adoption of this guidance will not impact our Financial Statements.

6


Table of Contents

MATRIXX INITIATIVES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)
3. Stock-Based Compensation
     The Company measures the cost of services received in exchange for equity instruments based on the grant-date fair value of the award and recognizes that cost in expense over the requisite service period. The Company uses the Black-Scholes option-pricing model in valuing option grants.
     The Company did not recognize any compensation expense for option awards during the three months ended June 30, 2010 or 2009. There were no options exercised in the three months ended June 30, 2010; however, 144,700 options were exercised in the three months ended June 30, 2009. No options were granted during the three months ended June 30, 2010 or 2009.
     The Company has granted restricted stock to directors, officers, and employees as part of its overall compensation plan. Compensation expense is based on the closing stock price on the grant date, and is amortized on a straight-line basis over the requisite service period. Stock-based compensation expense recognized in the quarter ended June 30, 2010, for restricted stock awards was approximately $106,000, or $65,000 after tax, compared to approximately $347,000, or $213,000 after tax, for the quarter ended June 30, 2009.
4. Basic and Diluted Income (Loss) Per Share
     Basic earnings (loss) per share are calculated using the weighted average number of common shares outstanding. Diluted earnings (loss) per share are computed on the basis of the weighted average number of common shares outstanding plus the effect of dilutive securities. The Company’s stock options and unvested restricted stock are considered dilutive securities and are included in the computation of diluted earnings (loss) per share using the “treasury stock” method.
     The table below summarizes the elements included in the calculation of basic and diluted net income (loss) per common share for the three months ended June 30, 2010 and 2009. Unvested restricted stock and options to purchase 310,762 and 285,225 shares of common stock for the three months ended June 30, 2010 and 2009, respectively, were not included in the computation of diluted loss per share because their effect would be anti-dilutive due to the loss reported in the quarters.
                 
    Three Months Ended  
    June 30,  
    2010     2009  
Net loss applicable to common shareholders
  $ (2,433,008 )   $ (22,832,252 )
 
           
Weighted average common shares outstanding — Basic
    9,287,580       9,169,829  
 
               
Dilutive Securities:
               
Options
           
Restricted Stock
           
 
           
Weighted average common shares outstanding — Diluted
    9,287,580       9,169,829  
 
           
Net loss per common share:
               
Basic
  $ (0.26 )   $ (2.49 )
Diluted
  $ (0.26 )   $ (2.49 )

7


Table of Contents

MATRIXX INITIATIVES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)
5. Inventories
     Inventories are stated at the lower of cost or market. The Company uses first-in, first-out method to value inventory. Inventories consisted of the following at June 30, 2010 and March 31, 2010:
                 
    June 30,     March 31,  
    2010     2010  
Raw materials and packaging
  $ 552,238     $ 623,808  
Finished goods
    6,455,443       5,543,001  
 
           
Total
  $ 7,007,681     $ 6,166,809  
 
           
6. Product Recalls and Withdrawals
     Zicam Cold Remedy Nasal Gel and Cold Remedy Gel Swabs Recall
     Matrixx establishes a reserve for product recalls and withdrawals on a product-specific basis when circumstances giving rise to the recall or withdrawal become known. Facts and circumstances related to the recall or withdrawal, including where the product affected by the recall or withdrawal is located (in inventory or at retail customers) and cost estimates for shipping and handling for returns, are considered when establishing a product recall or withdrawal reserve. These factors are updated and reevaluated each period and the related reserves are adjusted when the factors indicate that the recall or withdrawal reserve is either not sufficient to cover or exceeds the estimated product recall or withdrawal expenses.
     The Company received a warning letter from the Food and Drug Administration (the “FDA”) in the first quarter of fiscal 2010, dated June 16, 2009, regarding Zicam Cold Remedy Nasal Gel and Zicam Cold Remedy Gel Swabs. The FDA referred to complaints it had received of smell loss, also known as anosmia, associated with these products and asserted that the Company was in violation of FDA regulations by failing to file a new drug application for the products. The FDA also asserted that the products were misbranded under FDA regulations for failing to adequately warn of the risk of smell loss. Although the Company disagreed with the FDA’s allegations (see Note 7 — “Legal Proceedings” of this Report for more information on the Company’s position with respect to the FDA’s warning letter), the Company cooperated with the FDA and recalled the Zicam Cold Remedy Nasal Gel and Cold Remedy Swabs from the market.
     In the quarter ended June 30, 2009, the Company recorded a $9.0 million reserve for estimated costs to recall these products. The reserve charge was recorded in selling, general and administrative expense in the accompanying statement of operations for the three months ended June 30, 2009. As of June 30, 2010, the recall reserve has been exhausted and we do not anticipate recording any additional recall charges for the withdrawal of nasal Cold Remedy products that occurred in June 2009.
7. Legal Proceedings
     The Company is involved in various product liability claims and other legal proceedings. The Company’s legal expense for these lawsuits continues to have a significant impact on the results of operations as the Company defends itself against the various claims.
     Among the principal matters pending to which the Company is a party are the following:

8


Table of Contents

MATRIXX INITIATIVES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Product Liability Matters
     General. Since 2003, a number of lawsuits have been filed against us alleging that our Zicam Cold Remedy nasal gel products have caused the permanent loss or diminishment of the sense of smell or smell and taste. Prior to the Company’s receipt of the FDA’s June 16, 2009 warning letter (see Note 6 — “Product Recalls and Withdrawals”), the number of lawsuits filed against the Company was steadily declining; in fact, the numbers of pending lawsuits, plaintiffs, new lawsuits and potential claimants were at their lowest levels since early 2004.
     Since the Company’s receipt of the FDA warning letter, numerous product liability lawsuits have been filed against the Company, many of which cite the FDA warning letter as support for their claims. The lawsuits principally fall into two categories of product liability claims: (i) those alleging that our Zicam Cold Remedy nasal gel products caused the permanent loss or diminishment of the sense of smell or smell and taste (i.e., personal injury claims) and (ii) those seeking compensation for the purchase price of the Zicam Cold Remedy nasal gel products or various forms of equitable relief based on allegations that the Company misrepresented the safety and/or efficacy of such products to consumers (i.e., economic injury claims). All of the economic injury lawsuits have been filed as class actions but none of the classes has been certified to date (uncertified class actions are referred to as “putative” class actions). On October 9, 2009, a judicial panel ordered the centralization and transfer of a number of economic injury and personal injury actions pending in federal court to a federal court in the District of Arizona pursuant to federal multidistrict litigation procedures (see “Multi-District Litigation Matters” below for a discussion of the cases that have been consolidated and transferred). The Company intends to vigorously defend itself against each of these lawsuits.
     Our Position and Our Response. We believe the claims made in these lawsuits are scientifically unfounded and misleading and we disagree strongly with the FDA’s allegations that Zicam Cold Remedy nasal gel products may be unsafe and that they were unlawfully marketed. The Company’s position is supported by the cumulative science, a multi-disciplinary panel of scientists, and the decisions of 10 separate federal judges in 10 different cases in multiple jurisdictions. In October 2009, in response to the Company’s request, the FDA advised the Company that it was unwilling to reverse its position. On November 16, 2009, the Company filed its response to the FDA’s warning letter. In its response, the Company reiterated its position that there is no valid scientific evidence that Zicam nasal Cold Remedy products are unsafe and requested the FDA to withdraw the warning letter. By letter dated March 4, 2010, the FDA reaffirmed its original position and denied the Company’s request.
     Product Safety. There is no known causal link between the use of Zicam Cold Remedy nasal gel and impairment of smell or smell and taste. To date, no plaintiff has ever won a product liability case against the Company on those grounds. The Company believes that upper respiratory infections and nasal and sinus disease are the most likely causes of the smell dysfunctions reported by some consumers. One of the most common causes of smell disorders is the cold itself, the very condition our product is used to treat. Other causes are sinusitis and rhinitis, conditions which are sometimes present when our product is used.
     Federal law requires that the testimony of a scientific or medical expert witness be reliable and based on valid scientific data and analysis before it can be allowed into evidence. To date, the Company has submitted motions in ten federal lawsuits against the Company challenging the reliability and admissibility of the testimony of expert witnesses who claim that Zicam Cold Remedy is capable of causing or has caused smell and taste loss. To date, the courts have ruled in the Company’s favor on all ten motions. Each court has ruled that the theory that Zicam Cold Remedy nasal gel causes smell loss, as promoted by the plaintiffs’ experts, has no reliable scientific support and was reached without application of proper scientific standards and procedures. Federal courts have made such rulings against the three most prominent causal experts that plaintiffs have hired to date as well as various other expert witnesses.
     In addition, on April 3, 2008, jurors in a California case unanimously found that Zicam was not the cause of plaintiff’s smell loss.

9


Table of Contents

MATRIXX INITIATIVES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
     Product Effectiveness. Our claims and advertising are subject to the requirements of the Federal Trade Commission Act (“FTC”). On March 21, 2006, the FTC’s East Central Region (Cleveland, Ohio office), initiated a detailed inquiry to determine whether the Company engaged in unfair or deceptive acts or practices in violation of the Federal Trade Commission Act in connection with the Company’s advertising and promotional activities for several of the Company’s nasal and oral cold remedy products, including Zicam Cold Remedy Nasal Gel and Zicam Cold Remedy Swabs — the products that are the subject of the FDA warning letter. As part of the inquiry, the FTC requested and received, among other things, the Company’s documentation regarding product safety, including side effects, adverse events and consumer complaints, and efficacy, including the scientific proof establishing the efficacy claims made by the Company. Following a nearly year-long process, during which the Company provided the FTC with over 65,000 pages of documentation and met with the FTC to discuss the information, on March 5, 2007, the FTC notified the Company that it was no longer pursuing the inquiry.
     Total Pending Product Liability Lawsuits. As of August 1, 2010, the Company is aware of 231 pending product liability lawsuits against the Company, involving 794 plaintiffs. Of those cases, 174 are pending in Federal court and 57 are pending in State court.
     Cases since March 31, 2010 (Pending in Federal Courts): The Company is aware of the following pending federal court cases, covering 56 named plaintiffs, which were filed against and/or served on the Company between March 31, 2010 and August 1, 2010.
     Personal Injury:
         
Date Filed   United States District Court   Named Plaintiff
4/1/2010
  Northern District, Texas   McRae, S.
4/5/2010   New Jersey   Martinez, M.
4/7/2010   Central District, California   Shapiro, R.
4/9/2010   Arizona   Gardner, C.
4/9/2010   Western District, Missouri   Smith, R.C.
4/22/2010   Southern District, Mississippi   Rochelle, C.
4/27/2010   Puerto Rico   Quinones-Rodriguez, L.
5/6/2010   South Carolina   Spradley, D.
5/20/2010   Eastern District, Tennessee   Lyons, M.
5/21/2010   Western District, Michigan   Alisea, I.
5/26/2010   Central District, California   Coggins, E
5/28/2010   Western District, Missouri   Beatty, D.
5/28/2010   Western District, Missouri   Bowers, B.
5/28/2010   Western District, Missouri   Wadkins, J.
6/3/2010   Eastern District, Missouri   Schwartz, J.
6/9/2010   Western District, Tennessee   Terhune, G.
6/9/2010   Western District, Tennessee   Childress, J.
6/9/2010   Western District, Tennessee   Bell, V.
6/14/2010   Western District, Missouri   Goble, K.
6/14/2010   Western District, Missouri   Vance, C.
6/14/2010   Western District, Missouri   Morgan, S.
6/14/2010   Western District, Louisiana   Boozman, M.
6/15/2010   Western District, Kentucky   Stokes, S.
6/15/2010   Arizona   Johnson, R.
6/15/2010   Arizona   Vincent, M.
6/15/2010   Arizona   Swindell, J.
6/15/2010   Arizona   Tio, R.
6/30/2010   Western District, Missouri   Conti, A.
6/30/2010   Massachusetts   Surette, R.
6/30/2010   Arizona   Kirsch, C.

10


Table of Contents

         
Date Filed   United States District Court   Named Plaintiff
7/1/2010   Southern District, Ohio   Warrington, J.
7/14/2010   Arizona   Barton, J.
7/15/2010   Arizona   Holloway, S.
7/15/2010   Arizona   Wilhite, J.
7/15/2010   Arizona   Ponthieux, S.
7/15/2010   Arizona   Murter, J.
7/20/2010   Maryland   Carter, C.
7/20/2010   Maryland   Davis, L.
7/20/2010   Maryland   Floyd, R.
7/20/2010   Maryland   Foley, L.
7/20/2010   Maryland   Hamilton, A.
7/20/2010   Maryland   Jackson, A.
7/20/2010   Maryland   Jackson, R.
7/20/2010   Maryland   Lipscomb, D.
7/20/2010   Maryland   Moore, B.
7/20/2010   Maryland   Pilkenton, L.
7/20/2010   Maryland   Rentch, B.
7/20/2010   Maryland   Saur, M.
7/20/2010   Maryland   Short, J.
7/27/2010   Arizona   Cochren, M.
     Putative Class Actions for Economic Injury: None.
     Multi-District Litigation Matters. As previously disclosed, in August 2009, the Company filed a motion to consolidate and transfer all of the personal injury and economic injury matters, including any purported class actions, pending against the Company in federal court to the District of Arizona, pursuant to federal multidistrict litigation (“MDL”) procedures. On October 9, 2009, the Judicial Panel on Multidistrict Litigation (“Panel”) established MDL No. 2096, In Re: Zicam Cold Remedy Marketing and Sales Practices Litigation, and centralized the economic injury and personal injury actions that involve common questions of fact before a federal court in the District of Arizona. With one exception, the Panel transferred all of the economic injury cases at issue in the original MDL request. The Panel also began the MDL transfer process for the remaining economic injury and personal injury matters pending against the Company in federal courts across the country. The plaintiffs in these remaining cases will have the opportunity to object to the MDL transfer of their specific case. The Panel determined that the case of Hohman et. al. vs. Matrixx Initiatives, Inc. et. al. (filed June 18, 2009, Northern District of Illinois) did not involve sufficient common questions of fact to allow for consolidation and transfer to the MDL at that time. The Company expects any federal economic injury and personal injury matters filed in the future to be transferred and consolidated pursuant to the MDL transfer process, subject to the plaintiffs’ opportunity to object.
     Cases since March 31, 2010 (Pending in State Courts). The Company is aware of the following state court cases, covering 135 named plaintiffs, which were filed against and/or served on the Company between March 31, 2010 and August 1, 2010:
     Personal Injury:
         
Date Filed   Court   Named Plaintiff
4/1/2010   Maricopa County, AZ   Alston, B.
4/19/2010   Maricopa County, AZ   Miller, R.
4/19/2010   Maricopa County, AZ   Maxfield, W.
4/19/2010   Maricopa County, AZ   Colbert, D.
5/4/2010   Maricopa County, AZ   Maaskant, P.
5/11/2010   Maricopa County, AZ   Brooks, D.
5/13/2010   San Francisco County, CA   Parson, J.
6/14/2010   Maricopa County, AZ   Dubois, S.
6/18/2010   Maricopa County, AZ   Krupp, D.
6/18/2010   Maricopa County, AZ   Harrison, L.
6/18/2010   Maricopa County, AZ   Goad, S.
6/22/2010   Maricopa County, AZ   Lewotsky, L.
6/22/2010   Maricopa County, AZ   McCloy, M.
7/8/2010   Maricopa County, AZ   Michaels, A.
7/9/2010   St. Clair County, IL   MacDonald, C.
7/21/2010   Kootenai County, ID   Richmond, J.
7/23/2010   Jerome County, ID   Huettig, L.
7/26/2010   Maricopa County, AZ   Allen, R.
7/28/2010   Asotin County, WA   Hill, S.

11


Table of Contents

     Putative Class Actions for Economic Injury: None.
     Settlement with Certain Claimants. In July 2010, the Company entered into settlement agreements with approximately 46 claimants who had previously threatened to file lawsuits against the Company. The individual settlement amounts were $5,000 or less per claimant and were charged to our litigation reserves (see “Product Liability Litigation Reserves” below). The settlement documents for all claimants acknowledge that Matrixx denies any liability to them. Those who are eligible and elect to participate in the settlement program dismiss their claims with prejudice and provide written releases of their claims against the Company in return for their participation. Each of the claimants alleged use of the Company’s single hole Cold Remedy nasal gel product, which was last sold in 2005. To date, the Company has never settled claims relating to nasal gel products other than the single hold product.
     Potential Claimants. Approximately 500 potential claimants have advised the Company by means of a written notice that they are considering filing a lawsuit against, or are interested in pursuing settlement negotiations with, the Company. The Company is in the process of determining the nature or basis of their purported claims and when or if these potential claimants will ultimately file one or more lawsuits against the Company.
     Plaintiffs’ law firms may continue to solicit potential claimants and, as a result, additional lawsuits may be filed against us. We cannot predict the outcome of the litigation, but we will defend ourselves vigorously. If any liability were to result from one or more of these or future lawsuits, we believe our financial results could be materially impacted. Our financial results also could be materially impacted by the adverse publicity that may result from the lawsuits.
     Litigation Reserves. As of December 31, 2005, the Company established a reserve of $1.3 million for any future payment of settlement or losses related to the Cold Remedy litigation. This reserve was based on certain assumptions, some of which are described below, and was the amount, excluding defense costs, the Company believed it could reasonably estimate would be spent to resolve the remaining cases that had been filed or to resolve matters with the potential claimants. Some of the significant factors that were considered in the establishment of the reserve were as follows: the actual costs incurred by the Company up to that time in resolving several claims; the development of the Company’s legal defense strategy; settlements; and the number of cases that remained pending against the Company. There are events, such as the dismissal of any of the cases, the filing of new lawsuits, threatened claims, the outcome of a trial, rulings on pending evidentiary motions, or adverse publicity that may have an impact on the Company’s conclusions as to the adequacy of the reserve for the pending product liability lawsuits. The Company maintained a $740,000 reserve balance as of June 30, 2010, equal to the $740,000 reserve at March 31, 2010. The settlement with 46 potential claimants for $222,500, mentioned above, was paid from the reserve in July 2010. The decline in the reserve balance was due to settlements of certain claims. However, following the Company’s receipt of the FDA’s warning letter and the resulting increase in the number of product liability lawsuits being filed, the amounts that may be spent to resolve matters with actual and potential claimants could be higher than our reserve. The Company will continue to review the product liability situation and will adjust the litigation reserve in the future when we can reasonably estimate changes in the amounts and likelihood of resolving the claims. Litigation is inherently unpredictable and excessive verdicts do occur. Although we believe we have substantial defenses in these matters, we could, in the future, incur judgments or enter into settlements of claims that could have a material adverse effect on our results of operations in any particular period.

12


Table of Contents

MATRIXX INITIATIVES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Securities Litigation Matters
     Two class action lawsuits were filed in April and May 2004 against the Company, our previous President and Chief Executive Officer, Carl J. Johnson, and William J. Hemelt, our President and Chief Executive Officer, alleging violations of federal securities laws. On January 18, 2005, the cases were consolidated and the court appointed James V. Siracusano as lead plaintiff. The amended complaint also includes our Vice President of Research and Development, Timothy L. Clarot, as a defendant and was filed March 4, 2005. The consolidated case is Siracusano, et al. vs. Matrixx Initiatives, Inc., et al., in the United States District Court, District of Arizona, Case No. CV04-0886 PHX DKD. Among other things, the lawsuit alleges that between October 2003 and February 2004, we made materially false and misleading statements regarding our Zicam Cold Remedy products, including failing to adequately disclose to the public the details of allegations that our products caused damage to the sense of smell and of certain product liability lawsuits pending at that time. We filed a motion to dismiss this lawsuit and, on March 8, 2006, the Company received an Order dated December 15, 2005 granting the motion to dismiss the case, without prejudice. On April 3, 2006, the plaintiff appealed the Order to the United States District Court of Appeals, Ninth Circuit and on October 28, 2009, the Ninth Circuit Court reversed the decision of the United States District Court, District of Arizona. On June 14, 2010, the United States Supreme Court granted certiorari review and will hear the case during the Court’s 2010-2011 term.
     A separate putative class action was filed on July 17, 2009 against the Company; William J. Hemelt, our President and Chief Executive Officer; Samuel C. Cowley, our Executive Vice President of Business Development, General Counsel and Secretary; Timothy L. Clarot, our Vice President of Research & Development; and Carl J. Johnson, our former President and Chief Executive Officer, alleging violations of federal securities laws. Shapiro et al. vs. Matrixx Initiatives, Inc. et al., in the United States District Court, District of Arizona, Case No. 2:09-cv-01479-ECV (the “Shapiro” action). The lawsuit alleges that the Company and the named officers failed to disclose to the FDA and to the public information about adverse events regarding the Zicam Cold Remedy nasal gel products and that the Company and such officers made false and misleading statements regarding the Company’s compliance with FDA regulations. The Company believes these allegations are without merit and intends to vigorously defend the lawsuit.
     In accordance with and subject to the provisions of the Company’s Certificate of Incorporation, Messrs. Hemelt, Cowley, Clarot and Johnson will be indemnified by the Company for their expenses incurred in defending each of these lawsuits and for any other losses which they may suffer as a result of these lawsuits. The Company has submitted each of these matters to its insurance carriers. If any liability were to result from these lawsuits that is not covered by insurance, we believe our financial results could be materially impacted.
Shareholder Derivative Lawsuits
     On September 11, 2009, a shareholder derivative lawsuit was filed by Timothy Hall, on behalf of the Company, against all of the Company’s current directors and the following current and former officers of the Company: William Hemelt, Samuel Cowley and Carl Johnson. The lawsuit alleges, among other things, that the officers and directors named in the complaint violated their fiduciary duties to the Company by (i) misrepresenting the safety of the Zicam Cold Remedy nasal gel products, (ii) failing to warn consumers that use of the Zicam Cold Remedy nasal products could result in anosmia and (iii) failing to disclose reports of anosmia to the FDA and otherwise misrepresenting the Company’s compliance with FDA regulations. Timothy Hall v. William J. Hemelt, et al., United States District Court, District of Arizona.

13


Table of Contents

MATRIXX INITIATIVES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
     On September 18, 2009, a shareholder derivative lawsuit was filed by Theodore C. Klatt, on behalf of the Company, against all of the Company’s current directors and the following current and former officers of the Company: William Hemelt, Samuel Cowley, Carl Johnson, Timothy Clarot and James Marini. The lawsuit alleges, among other things, that the officers and directors named in the complaint violated their fiduciary duties to the Company by (i) misrepresenting the safety of the Zicam Cold Remedy nasal gel products, (ii) failing to warn consumers and shareholders that use of the Zicam Cold Remedy nasal products could result in anosmia and (iii) failing to disclose reports of anosmia to the FDA and otherwise misrepresenting the Company’s compliance with FDA regulations (Theodore C. Klatt v. William J. Hemelt, et al., United States District Court, District of Arizona).
     On October 14, 2009, the parties filed a stipulation to transfer the Klatt action and consolidate it with the Hall action. On November 4, 2009, the stipulation was granted. On January 19, 2010, the Company moved for a stay of the consolidated derivative action pending the outcome of the Shapiro action (discussed under “Securities Litigation Matters” above), which the Court granted on March 1, 2010.
     On November 20, 2009, a shareholder derivative lawsuit was filed by Bette-Ann Liguori, on behalf of the Company, against all of the Company’s current directors and certain of their spouses, and the following current and former officers and directors of the Company and certain of their spouses: Carl Johnson, Timothy Clarot, Timothy Connors, Lynn Romero, Michael Voevodsky, James Marini, and Edward Faber (Liguori v. Egan, et al., Superior Court of the State of Arizona, County of Maricopa). The lawsuit alleges, among other things, that the officers and directors named in the complaint violated their fiduciary duties to the Company by (i) misrepresenting the safety of the Zicam Cold Remedy nasal gel products, (ii) failing to warn consumers and shareholders that use of the Zicam Cold Remedy nasal products could result in anosmia and (iii) failing to disclose reports of anosmia to the FDA and otherwise misrepresenting the Company’s compliance with FDA regulations. On January 19, 2010, the Company filed a motion to stay the action pending the outcome of the Shapiro action or, in the alternative, pending the outcome of the consolidated derivative action filed in Federal court. On May 18, 2010, the court granted defendants’ motion and ordered the parties to file a status report in six months.
     In accordance with and subject to the provisions of the Company’s Certificate of Incorporation, each of the named directors and current and former officers and spouses will be indemnified by the Company for their expenses incurred in defending each of these lawsuits and for any other losses that they may suffer as a result of these lawsuits.
Related Legal Matters — Informal Inquiries
     The Company has received an inquiry from several county district attorneys in one state regarding enforcement of certain consumer protection statutes involving our product packaging size. The Company is cooperating fully, but is unsure about what actions may be taken. The matter could result in fines or litigation over the Company’s alleged non-compliance with the applicable package size statutes. Based on information available to the Company, the Company does not believe this matter would have a material adverse impact on its operations, liquidity or cash flow.

14


Table of Contents

MATRIXX INITIATIVES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)
Legal Expense
     The Company is incurring significant legal expense for the lawsuits referenced above. As previously disclosed, the Company had a limited amount of product liability insurance to cover litigation expense, losses and/or settlements associated with claims that our Cold Remedy products caused a loss of smell. The insurer has determined the ultimate defense costs and claims associated with the anosmia allegations will likely exceed the policy limit of $5 million. To avoid ongoing administrative costs, in July 2010, the Company and its product liability insurer reached agreement that the insurer would pay the full amount of the $5.0 million policy to the Company. Based on this agreement, the Company recorded $2.2 million, in the quarter ended June 30, 2010, as reimbursement of legal expenses for defending claims previously made against that policy. This resulted in a net credit of $337,000 for product liability and regulatory related legal expense ($1.9 million prior to insurance reimbursement) in the quarter ended June 30, 2010, which compares to legal expense of $577,000 in the quarter ended June 30, 2009. The remaining $2.8 million, to be received from the insurer, will be applied against ongoing future legal expense. We expect to continue to incur legal expense of $1.3 million to $1.8 million per quarter before allocation of insurance proceeds.
8. Goodwill and Asset Impairment Charges
     Intangibles consist of goodwill (which is the excess of purchase price over the net assets of businesses acquired), intellectual property, and trademarks. Goodwill is not amortized but finite-lived intangibles are amortized using the straight-line method. The Company’s $15.0 million in goodwill was related to the Company’s acquisition of the 40% Zicam, LLC interest acquired from Zensano, Inc. in December 2001. The business of Zicam, LLC at that time was to develop and produce homeopathic nasal gel products based on a proprietary zincum gluconium delivery system.
     Goodwill and certain other assets must be tested upon a triggering event to identify potential impairments and the amount of any impairment loss. Following the June 16, 2009 FDA warning letter and subsequent recall of our Zicam Cold Remedy Nasal Gel and Zicam Cold Remedy Swabs, the Company concluded a triggering event had occurred and performed an impairment assessment as of June 30, 2009. The Company performed an assessment within the accounting fair value hierarchy, in which it evaluated, among other things, the impact of the foregoing events on the market’s perception of the value of the Company’s stock, the expected increase in legal activity, and the expected decline of Zicam product sales. The Company first determined the fair value using two valuation methodologies: (a) the income approach, which uses discounted cash flow projections, and (b) the market value approach, which uses quoted market prices or unobservable inputs that are corroborated by market data. The determination of fair value requires the use of significant judgment and estimates about assumptions that management believes were appropriate in the circumstances, although it is reasonably possible that actual performance will differ from these assumptions. The most significant assumptions include those relating to our ability to sell nasal gel Cold Remedy products in the future, our ability to introduce new nasal products, sales expectations of our other swab products, and market trading multiples for the Company.
     The assessment resulted in the Company recording charges of $23.9 million ($14.6 million after-tax) in the quarter ended June 30, 2009, to reduce the carrying amounts of goodwill and other tangible and intangible assets to fair value. These charges include: a non-cash impairment charge of $15.0 million related to the goodwill associated with the zincum gluconium nasal gel products; a non-cash impairment charge of $3.9 million to write-down the inventory value of nasal Cold Remedy products and other nasal application inventory; an impairment charge of $4.3 million ($3.4 million of which is non-cash) for a new swab manufacturing line that was built to produce our nasal swab product; and $616,000 for the unamortized amount of our Cold Remedy nasal gel patent. The charge was included in “Goodwill Impairment and Asset Impairments” in the accompanying statement of operations for the quarter ended June 30, 2009.

15


Table of Contents

MATRIXX INITIATIVES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)
     The following table sets forth the changes, discussed above, in the Company’s carrying amount of goodwill and certain other assets, measured at fair value on a nonrecurring basis during the quarter ended June 30, 2009:
Level 1: Quoted prices in active markets for identical assets or liabilities.
Level 2: Significant other observable inputs.
Level 3: Significant unobservable inputs.
                                 
                            Total Gains
    Level 1   Level 2   Level 3   (Losses)
$000s
                               
Goodwill
                ($15,040 )     ($15,040 )
Deposits
          ($4,284 )           ($4,284 )
Patent
          ($616 )           ($616 )
     In addition to the impairment charges associated with our nasal Cold Remedy products discussed above, in the quarter ended June 30, 2009, we recorded a charge of $420,000 to write down the value of patents and certain other assets associated with the development of an oral care product developed to reduce tartar. We do not anticipate launching this product on our own and determined the assets associated with the product’s development were impaired. This charge was recorded in research and development expense in the accompanying Financial Statements for the fiscal first quarter ended June 30, 2009.
9. Financial Instruments Fair Value
     The Company follows the FASB guidance that defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements for all financial assets and liabilities.
     Cash, cash equivalents, accounts payable and accounts receivable: Carrying amounts approximate fair value because of the short maturity of those instruments.
     Certificates of Deposit: The Company occasionally purchases certificates of deposit from FDIC-insured institutions at or below the FDIC-insured limits and all certificates of deposit have maturities of one year or less. The purchase price of each certificate of deposit is treated as its fair market value on the purchase date. We account for these certificates of deposit at amortized costs and they are held to maturity.
Item 2.   Management’s Discussion and Analysis of Financial Condition and Results of Operations
Overview
     The Company develops, markets and sells innovative, over-the-counter (OTC) healthcare products with an emphasis on those that utilize unique delivery systems. The Company currently markets its products within the U.S. $4.0-$5.0 billion overall cough and cold category at retail. Our Zicam products are sold in the cold remedy, allergy/sinus, cough and multi-symptom relief market groups of the overall cough and cold category. The Zicam Cold Sore and Healthy Z-ssentials products are also part of the cough/cold category. A mix of our products is currently available at all of the major food, drug, and mass merchant retailers.

16


Table of Contents

     The products we market are seasonal in nature, and sales at retail generally increase as the incidence of colds and flu rises. We record sales when products are shipped from our warehouse facilities to customers. During the July through September quarter, the Company’s sales volume is primarily affected by retailers stocking our products and ordering displays to prepare for the upcoming cough and cold season. Additional sales (re-orders) to retailers are highly dependent upon the incidence of illness within the population. Retail sales of our products are highest during the cough and cold season, which usually runs from October through March. We increase our advertising campaigns to coincide with the cough and cold season and generally realize higher advertising expense in the October through March time periods. Because of the seasonality of our business, results for any single quarter are not necessarily indicative of the results that may be achieved for the full fiscal year.
     We received a warning letter from the FDA on June 16, 2009 regarding Zicam Cold Remedy Nasal Gel and Zicam Cold Remedy Swabs. The FDA referred to complaints it had received of smell loss, also known as anosmia, associated with these products and asserted that the Company was in violation of FDA regulations by failing to file a new drug application for the products. The FDA also asserted that the products were misbranded under FDA regulations for failing to adequately warn of the risk of smell loss. Although the Company disagreed with the FDA’s allegations, the Company cooperated with the FDA and recalled the Cold Remedy Nasal Gel and Cold Remedy Swabs from the market.
     The FDA warning letter, the recall of Zicam Cold Remedy Nasal Gel and Zicam Cold Remedy Swabs, and the subsequent litigation have had a material adverse impact on our business. The recalled products accounted for approximately 40%, or $42.5 million, of our fiscal 2009 net sales and, prior to the recall, accounted for approximately $2.0 million of net sales in the quarter ended June 30, 2009. Our primary focus since the withdrawal of our nasal gel products has been the conversion of consumers that used our nasal Cold Remedy products to our oral Cold Remedy offerings. As a result, our promotional and marketing support primarily focuses on Zicam oral Cold Remedy products.
The Company’s fiscal first quarter, which ends June 30, is historically the lowest performing quarter in the fiscal year.
     Certain information is set forth below for our operations, expressed in thousands of dollars and as a percentage of net sales, for the periods indicated:
                                 
    3 Months Ended June 30,  
$000s   2010     % NS     2009     % NS  
Net Sales
  $ 3,208       100 %   $ 6,916       100 %
Marketing
  $ 2,594       81 %   $ 3,312       48 %
Sales
  $ 544       17 %   $ 617       9 %
General & Administrative
  $ 2,513       78 %   $ 12,273       177 %
Legal -Product Liability & Regulatory
  $ (337 )     (11 )%   $ 287       4 %
 
Total Selling, General, and Administrative
  $ 5,314       165 %   $ 16,489       238 %
 
Research & Development
  $ 530       17 %   $ 934       14 %
 
Goodwill & Asset Impairments
  $ 0       0 %   $ 23,867       345 %
 
     Net sales for the fiscal first quarter ended June 30, 2010 decreased to $3.2 million, compared to $6.9 million for the quarter ended June 30, 2009. The lower sales comparison is due to the loss of our nasal Cold Remedy products which, prior to their withdrawal, accounted for $2.0 million of net sales in the quarter ended June 30, 2009. In addition, sales of our congestion, allergy, and symptom relief products declined $1.3 million compared to sales in the quarter ended June 30, 2009. However, recent consumer consumption data comparing 4-week year-over-year trends following last year’s withdrawal of nasal Cold Remedy products, to the same period this year, shows growth of 5% for oral Cold Remedy and 7% for allergy/congestion products.

17


Table of Contents

     The Company incurred a net loss for the fiscal first quarter ended June 30, 2010 of approximately $2.4 million, or $(0.26) per diluted share, compared to a net loss of $22.8 million, or $(2.49) per diluted share, for the quarter ended June 30, 2009. Results for the quarter ended June 30, 2009 included pretax charges of $9.0 million to reserve for recall-related costs and $23.9 million for goodwill and other asset impairments.
     We expect net income (loss) in future periods to be significantly affected by the level of sales, the timing and amount of our advertising, research and development expenses, and the timing and amount of expenses incurred in defense of product liability litigation matters. Expenditures for advertising and research and development will vary by quarter throughout the year and could be significantly different in future periods than the amounts incurred in the same period in earlier years. We expect that advertising expenses will be highest during the cold season (third and fourth fiscal quarters). We anticipate quarterly earnings will continue to vary along with the seasonality of sales and the level of marketing and research and development expense.
     The Company’s management reviews several key indicators in evaluating overall performance:
  1)   We review our sales and net income performance against our annual goal for each. In fiscal 2011, the Company will focus on growing sales in our core Cold Remedy and Allergy/Sinus franchise and offsetting declines in our symptom relief and other cough/cold products. For fiscal 2011, the Company anticipates revenue increasing 3% to 5% above the $67.3 million achieved in fiscal 2010. We anticipate expense for litigation will be between $1.3 million and $1.8 million per quarter (prior to insurance reimbursement) in fiscal 2011. In addition, we expect to report net income between $2.0 and $3.0.
 
  2)   We monitor sales of our products at retail because increased consumer purchases of our products are an indicator of growth. For the rolling 52 weeks ended June 13, 2010, retail unit sales (as measured by three outlet syndicated scanner data, not including our largest customer, Wal-Mart and excluding nasal Cold Remedy) of our oral Cold Remedy products increased approximately 10% while sales of our allergy and congestion products declined approximately 13% over the comparable period in the previous year, while the entire cough and cold category was relatively unchanged. Recent consumer consumption data comparing 4-week year-over-year trends following last year’s withdrawal of nasal Cold Remedy products to the same period of this year, shows growth of 5% for oral Cold Remedy and 7% for allergy/congestion products.
 
  3)   We measure our ability to maintain strong gross margins on our products. During the quarter ended June, 2010, we realized an average gross margin of 58%, compared to the 60% average gross margin achieved in the prior year. Gross margins on our existing products generally vary between 65% and 80%. Due to the level of in-store promotional activity, relative to the low level of unit sales that occurred in the quarter, our average selling price per unit declined 5% in the quarter ended June 30, 2010, compared to the quarter ended June 30, 2009. This decline in average sales price affected gross margin for the quarter.
 
  4)   We evaluate our operating performance by reviewing, over time, our ability to decrease operating expenses as a percentage of net sales. We evaluate our ability to control operating expenses on an annual basis due to the seasonal fluctuations in quarterly net sales. We anticipate fiscal 2011 operating expenses will decline as a percentage of sales compared to the prior fiscal year.
 
  5)   We review the distribution and mix of our products by key national retailers. Our ten largest retail customers account for a substantial majority of our annual sales, and we encourage our largest customers to carry a mix of our highest-selling products. Retailers generally reset their cough and cold sections during the third calendar quarter of each year, at which time they add or discontinue products. We expect our ten largest retailers to have a net increase in Zicam oral Cold Remedy products on shelf during this year’s cold season. Although retailers are increasing the number of our products they sell, they are also increasing the number of store brand products that directly compete with our Zicam offerings. Store brand products are generally sold at a substantial discount to branded products. Store brand versions of our products may adversely affect our mix of products at retail as well as our sales levels.

18


Table of Contents

Critical Accounting Policies and Estimates
     Our consolidated financial statements and accompanying notes have been prepared in accordance with GAAP applied on a consistent basis. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods.
     We regularly evaluate the accounting policies and estimates that we use to prepare our consolidated financial statements. In general, management’s estimates are based on historical experience, information from third party professionals, and various other assumptions that are believed to be reasonable under the facts and circumstances. Actual results could differ from those estimates made by management.
     We believe that our critical accounting policies and estimates include the accounting for intangible assets and goodwill, accounting for income taxes, revenue recognition, accounting for sales adjustments (returns and allowances), accounts receivable and allowance for doubtful accounts, accounting for legal contingencies, and accounting for product recalls.
     Legal Contingencies. We are subject to lawsuits, investigations and claims arising out of the normal conduct of our business (see Note 7 — “Legal Proceedings” for additional information regarding our pending and threatened litigation and our reserves for product liability litigation). While we are vigorously defending the Company in these proceedings, the outcome of these and any other proceedings that may arise cannot be predicted with certainty. The Company is required to accrue a contingent loss when the loss is deemed probable and reasonably estimable. The Company maintained a $740,000 reserve balance as of June 30, 2010 and March 31, 2010. Following the Company’s receipt of the FDA’s warning letter and the resulting increase in the number of product liability lawsuits being filed, the amounts that may be spent to resolve matters with actual and potential claimants could be higher than our reserve. In July 2010, the Company entered into settlement agreements with approximately 46 claimants who had previously threatened to file lawsuits against the Company. The individual settlement amounts were $5,000 or less per claimant and were charged to our litigation reserves in July 2010. The Company will continue to review and adjust the litigation reserve in the future when we can reasonably estimate changes in the amounts and likelihood of resolving the claims.
     Intangible Assets and Goodwill. We recorded approximately $15.0 million in goodwill in connection with the acquisition of the 40% Zicam, LLC interest acquired from Zensano, Inc. in December 2001. Goodwill must be tested when a triggering event occurs or at least annually to identify a potential impairment and the amount of any impairment loss. Our fiscal 2009 annual valuation of goodwill (as of September 1, 2008) was completed in January 2009 and no impairment was identified. In connection with the Company’s receipt of the FDA warning letter and the resulting recall of our Cold Remedy Nasal Gel and Cold Remedy Swabs, as well as the associated negative publicity, impact on the market’s perception of the value of the Company’s stock, higher legal activity, and the expected decline of Zicam product sales, the Company performed an impairment assessment as of June 30, 2009, which resulted in the Company recording charges to reduce the book value of goodwill and other intangible assets.
     The determination of fair value requires the use of significant judgment and estimates about assumptions that management believes were appropriate in the circumstances, although it is reasonably possible that actual performance will differ from these assumptions. The most significant assumptions included those relating to our ability to sell nasal gel Cold Remedy products in the future, our ability to introduce new nasal products, sales expectations of our other swab products, and market trading multiples for the Company. These charges include: a non-cash impairment charge of $15.0 million related to the goodwill associated with the acquisition of zincum gluconium nasal gel products and $616,000 for the unamortized amount of our Cold Remedy nasal gel patent. These charges were recorded in the quarter ended June 30, 2009 and are reflected in goodwill and Asset Impairments in our Financial Statements for the quarter ended June 30, 2009. In addition, due to our inability to commercialize our oral care product developed to reduce tartar, we recorded a charge of $420,000 to write down the value of patents and certain other assets associated with the development of that product in the quarter ended June 30, 2009. We do not

19


Table of Contents

anticipate launching this product on our own and determined the assets associated with the product’s development were impaired. This charge was recorded in research and development expense.
     Income Taxes. The provision for, or benefit from, income taxes is calculated using the asset and liability method, under which deferred tax assets and liabilities are recorded based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The Company has recorded deferred tax assets associated with tax loss carrybacks and carryforwards. These deferred tax asset amounts increased due to the Company’s fiscal 2010 operating loss. Deferred tax assets are evaluated on a quarterly basis to determine whether a valuation allowance is required. The Company assesses whether a valuation allowance should be established based on its determination of whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets depends primarily on the generation of future taxable income during the periods in which those temporary differences become deductible. Judgment is required in determining the future tax consequences of events that have been recognized in the Company’s consolidated financial statements and/or tax returns. Differences between anticipated and actual outcomes of these future tax consequences could have a material impact on the Company’s consolidated financial position or results of operations.
     Revenue Recognition. The Company recognizes revenue from product sales when the risks and rewards of ownership have transferred to the customer, which is considered to have occurred upon shipment of the finished product to retailers.
     Sales Adjustments. The Company routinely enters into arrangements with its retail customers to support sales programs that increase sales of our products to consumers. Such programs are based primarily on customer purchases and other factors such as sales to consumers. The programs include sales incentives, promotional allowances, coupons, rebates, and slotting fees. The programs involve fixed amounts or percentages of sales to customers. Reserves for such programs are calculated based on an assessment of purchases and performance under the programs and any other specified factors. While the majority of sales adjustment amounts are readily determinable at period end and do not require estimates, certain of the sales adjustments require management to make estimates. In making these estimates, management considers all available information, including the overall business environment, historical trends and information from customers.
     The estimate for product returns is based on our historical experience of sales to retailers and is reviewed regularly to reflect estimated product returns. We review the return provision at least quarterly and adjust the reserve amounts if actual product returns differ materially from our reserve percentage. Additionally, we adjust the returns provision when a determination is made that a product will be discontinued, either in whole or by certain retailers. Should the actual level of product returns vary significantly from our estimates, our operating and financial results would be materially affected.
     We record reserves for sales programs and returns as sales adjustments that offset revenue in the period the related revenue is recognized. Sales adjustments totaled $2.1 million and $3.6 million for the three months ended June 30, 2010 and 2009, respectively. Management believes that the reserves recorded for customer programs at June 30, 2010 are adequate and proper.
     Accounts Receivable and Allowance for Doubtful Accounts. The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in the Company’s existing accounts receivable. In recent years, the retail channel has experienced shifts in market share among competitors, causing some retailers to experience liquidity problems. There is a risk that customers will not pay, or that payment may be delayed, because of bankruptcy or other factors beyond the Company’s control. We increased the allowance for doubtful accounts from 0.02% of gross sales to 0.05% of gross sales for fiscal 2011. We review the allowance for doubtful accounts at least monthly and adjust the allowance amounts if actual or probable losses differ materially from our reserve percentage.
     Product Recalls. The Company establishes a reserve for product recalls and withdrawals on a product-specific basis when circumstances giving rise to the recall or withdrawal become known. Facts and circumstances related to the recall or withdrawal, including where the product affected by the recall or withdrawal is located (in inventory or at retail customers), and cost estimates for shipping and handling for returns are considered when establishing a product recall or withdrawal reserve. These factors are updated

20


Table of Contents

and reevaluated each period and the related reserves are adjusted when the factors indicate that the recall or withdrawal reserve is either not sufficient to cover or exceeds the estimated product recall or withdrawal expenses.
     For the quarter ended June 30, 2009, the Company recorded a $9.0 million reserve for estimated costs to recall the Cold Remedy Nasal Gel and Cold Remedy Swabs. The reserve charges were recorded in selling, general and administrative expense in the accompanying Financial Statements.
Results of Operations for the Three Months Ended June 30, 2010 Compared to the Three Months Ended June 30, 2009
     Certain information is set forth below for our operations expressed in $000’s and as a percentage of net sales for the periods indicated:
                                 
    Three Months Ended June 30,  
    2010     2009  
Net sales
  $ 3,208       100 %   $ 6,916       100 %
Cost of sales
    1,333       42       2,793       40  
 
                       
Gross profit
    1,875       58       4,123       60  
Selling, general and administrative
    5,314       166       16,489       238  
Research & development
    530       17       934       14  
Goodwill Impairment
    0             15,040       217  
Asset Impairments
    0             8,827       127  
 
                       
Loss from operations
    (3,969 )     (124 )     (37,167 )     (537 )
Interest and other income
    16       1       47       1  
Interest expense
                       
 
                       
Loss before income taxes
    (3,953 )     (123 )     (37,120 )     (537 )
Income taxes
    (1,520 )     (47 )     (14,287 )     (207 )
 
                       
 
                               
Net Loss
  $ (2,433 )     (76 )%   $ (22,832 )     (330 )%
 
                       
Net Sales
     Net sales for the three months ended June 30, 2010 were $3.2 million, versus net sales of $6.9 million for the quarter ended June 30, 2009. The decrease in net sales, for the quarter ended June 30, 2010 versus 2009, reflects the June 2009 withdrawal of nasal Cold Remedy products, which accounted for $2.0 million of net sales in the quarter ended June 30, 2009. In addition, sales of our congestion, allergy, and symptom relief products declined $1.3 million compared to sales in the quarter ended June 30, 2009. Our average selling price per unit declined 5% in the quarter ended June 30, 2010, compared to the quarter ended June 30, 2009. The decline in average sales price was primarily due to the level of in-store promotional activity, relative to the low level of unit sales that occurred in the quarter.
     Since the June 2009 recall of our nasal Cold Remedy products, our primary focus has been to convert consumers that used our nasal Cold Remedy products to our oral Cold Remedy offerings and to support our allergy/congestion business. Recent consumer consumption data comparing 4-week year-over-year trends following last year’s withdrawal of nasal Cold Remedy products, to the same period this year, shows growth of 5% for our oral Cold Remedy products and 7% for our allergy/congestion products.
Cost of Sales
     For the quarter ended June 30, 2010, our cost of sales decreased to $1.3 million, compared to $2.8 million for the quarter ended June 30, 2009. The decrease was primarily due to the lower number of units sold.
Gross Profit
     Gross profit for the three months ended June 30, 2010 was approximately $1.9 million, compared to gross profit of approximately $4.1 million for the quarter ended June 30, 2009. The decreased gross profit is primarily attributable to the lower net sales recorded during the quarter, compared to the prior year. Gross margin for the quarter ended June 30, 2010 was 58%, compared to 60% in the comparable quarter

21


Table of Contents

ended June 30, 2009. The gross margin decline is attributable to the lower average net unit sales price realized in the quarter. Gross margin is affected by the relative mix of products sold, promotional activity, and changes in product sales prices and costs.
Selling, General & Administrative (SG&A)
     SG&A expense for the quarter ended June 30, 2010 was approximately $5.3 million, compared to approximately $16.5 million in the quarter ended June 30, 2009. The decreased SG&A expense is primarily attributable to $9.0 million that was recorded in the quarter ended June 30, 2009 to reserve for recall-related charges associated with the withdrawal of nasal Cold Remedy products. In addition, marketing expense declined $719,000 in the quarter ended June 30, 2010, compared to the prior year. The higher level of marketing expense in the quarter ended June 30, 2009 reflects the high level of public relations activities that occurred in June 2009 responding to inquiries surrounding the FDA warning letter and subsequent recall of nasal Cold Remedy products.
     In addition, legal expense associated with litigation and regulatory activities was affected by the recording of $2.2 million of insurance reimbursement, which resulted in a net credit of $337,000 for legal expense in the quarter ended June 30, 2010, versus legal expense of $577,000 in the quarter ended June 30, 2009 (see Note 7 — “Legal Proceedings — Legal Expense,” for more information regarding insurance reimbursement).
Research and Development
     Research and development expense was approximately $530,000 in the quarter ended June 30, 2010, versus $934,000 in the quarter ended June 30, 2009. The timing of research and development spending can vary throughout the year and is not generally associated with our seasonal sales patterns.
Goodwill and Asset Impairments
     In the prior year’s fiscal first quarter and in connection with the Company’s receipt of the FDA warning letter and the resulting recall of our Cold Remedy Nasal Gel and Cold Remedy Swabs, the Company performed an impairment assessment as of June 30, 2009, in which it evaluated, among other things, the impact of the foregoing events on the market’s perception of the value of the Company’s stock, the expected increase in legal activity, and the expected decline of total product sales. The assessment resulted in the Company recording a charge of $23.9 million to reduce the carrying amounts of goodwill and other tangible and intangible assets to fair value. This charge includes a non-cash impairment charge of $15.0 million related to the goodwill associated with the acquisition of the zincum gluconium nasal gel products; a non-cash impairment charge of $3.9 million to write-down the inventory value of nasal Cold Remedy products and other nasal application inventory; an impairment charge of $4.3 million ($3.4 million of which is non-cash) for a new swab manufacturing line that was built to produce our nasal swab product; and $616,000 for the unamortized amount of our Cold Remedy nasal gel patent. There were no impairment charges recorded in the quarter ended June 30, 2010.
Interest & Other Income
     Interest and other income was approximately $16,000 in the quarter ended June 30, 2010 versus approximately $47,000 in the quarter ended June 30, 2009. The decline in interest income reflects lower interest rates and lower levels of cash. There was no interest expense in the quarters ended June 30, 2010, or 2009.
Income (Loss) Before Income Taxes
     Loss before income tax benefits for the three months ended June 30, 2010 was approximately $4.0 million, compared to a loss of approximately $37.1 million for the quarter ended June 30, 2009. The lower loss in the quarter ended June 30, 2010, reflects the $32.9 million of recall charges and goodwill and asset impairments recorded in the quarter ended June 30, 2009 (discussed above). We expect that income (loss) in future periods will be significantly impacted by the sales levels of our products, product introductions, and changes in our advertising, research and development, and legal expenses. We anticipate quarterly operating results will continue to vary along with the seasonality of sales and expenses.

22


Table of Contents

Income Taxes
     We recorded a benefit for income taxes at our combined estimated annual effective tax rate of approximately 38.5%. Due to the loss from operations incurred in the quarter ended June 30, 2010, we recognized an income tax benefit of approximately $1.5 million, compared to a benefit of $14.3 million in the quarter ended June 30, 2009.
Net Income (Loss)
     Net loss was approximately $2.4 million in the quarter ended June 30, 2010, compared to a net loss of approximately $22.8 million in the quarter ended June 30, 2009.
Liquidity and Capital Resources
     As of June 30, 2010, our cash, cash equivalents, and certificates of deposit balance was $28.3 million, compared to $30.2 million at March 31, 2010. The Company generally invests the majority of excess cash directly in a fund of U.S. Treasury Securities, U.S. government securities and repurchase agreements, and bank certificates of deposit insured by the U.S. government.
     Our working capital was $42.5 million as of June 30, 2010, compared to $44.4 million at March 31, 2010. During the quarter ended June 30, 2010, trade receivables decreased to $1.6 million from $5.4 million at March 31, 2010. The decrease in accounts receivable reflects the timing of orders and a lower level of sales in the first quarter. The Company’s principal source of liquidity is cash generated from sales of our products to retailers and distributors. The majority of sales are given 30 day credit terms; however, payment terms are occasionally extended, as retailers begin to increase inventory of our products prior to the onset of the cough and cold season. The Company records an estimated allowance for potentially uncollectible accounts, which is reviewed on a monthly basis. We believe our allowance as of June 30, 2010 is adequate. As a result of the Company’s fiscal 2010 operating loss, the Company recorded income tax receivables and deferred tax assets associated with tax loss carrybacks and tax credit carryforwards. We anticipate receiving tax refunds of approximately $5.5 million during fiscal 2011. Differences between anticipated and actual outcomes of these tax assets could have a material impact on the Company’s cash position in future periods.
     The changes in accounts receivable, inventory, accounts payable and accrued expenses largely reflects the seasonal nature of the Company’s business. Our working capital requirements fluctuate with the seasonality of our sales and are generally highest in the July through September quarter. The Company records the bulk of its sales, which is reflected in higher accounts receivable, in the second, third, and fourth fiscal quarters; generally builds inventory during the first through third fiscal quarter periods; and advertises its products, which is generally the largest component of accrued expenses, primarily in the third and fourth fiscal quarters. Although affected by the build-up of inventory, accounts payable and accrued expenses are more significantly affected by advertising spending. We do have working capital requirements arising from the increase of inventory and accounts receivable in excess of the increase in accounts payable, but these vary throughout the year reflecting the seasonal nature of our business. Generally, to the extent our operations are profitable, our business is cash flow positive.
     The Company is involved in various product liability claims and other legal proceedings. The Company’s legal expense for these lawsuits continues to have a material impact on the results of operations and requires a significant use of cash as the Company defends itself against the various claims. Litigation is inherently unpredictable and excessive verdicts do occur. Although we believe we have defenses in these matters, we could, in the future, incur judgments or enter into settlements of claims that could have a material adverse effect on our cash position in any particular period. To avoid ongoing administrative costs, the Company and its insurer reached an agreement in July 2010 that the insurer would pay to the Company, the full amount of the $5.0 million policy. Based on this agreement, the Company recorded $2.2 million, in the quarter ended June 30, 2010, as reimbursement of legal expenses incurred to date for defending claims made against that policy. The remaining $2.8 million will be applied to future legal expenses and/or settlements.
     Historically, the Company has had low capital expenditures because we rely on third party manufacturers to produce our products. Typical capital expenditures include investments in technology, office furniture, leasehold improvements, and small tooling requirements. The Company leased new

23


Table of Contents

corporate office and R&D space in March 2008 and invested approximately $650,000 in capital and tenant improvements, which we amortize over the term of the lease (approximately five years). The Company occasionally provides deposits and prepayments to our manufacturers to improve and increase manufacturing capabilities for our products. In 2006, the Company invested $4.2 million for an automated manufacturing line that produces our swab products. Based on the sales growth of our swab products, and our previous assumptions as to continued growth, we commissioned the building of a second manufacturing line to produce swab products at the end of fiscal 2009. However, due to the recall of our Cold Remedy swab product, we determined the new swab manufacturing line was impaired and, during the quarter ended June 30, 2009, we recorded a charge of $4.3 million to reduce the carrying amount of the new manufacturing line to fair value.
     We believe that our existing capital resources will be sufficient to fund our operations and capital requirements for at least the next 12 months.
     As discussed in more detail in Part II, Item 2. “Issuer Purchases of Equity Securities” of this Report, the Board of Directors of the Company approved a stock repurchase program, effective January 26, 2009, which permits the Company to purchase up to 1 million shares of the Company’s common stock. Concurrent with its approval of this repurchase program, the Board of Directors terminated the repurchase program previously authorized in April 2004. The Company does not anticipate repurchasing shares of its common stock on the open market for the foreseeable future. However, during the quarter ended June 30, 2010, the Company repurchased 31,204 shares of common stock, with an aggregate value of $153,820 from employees in satisfaction of their applicable tax withholding obligations on the vesting of restricted stock awards. Shares so surrendered are repurchased pursuant to the applicable award agreements and not pursuant to publicly-announced share repurchase programs.
Off-Balance Sheet Arrangements
     As of June 30, 2010, we did not have any off-balance sheet arrangements.
Contractual Obligations
     We have entered into certain long-term contractual obligations that will require various payments over future periods as follows:
                                         
            Contractual Cash Obligations          
            (In thousands of dollars)          
    Payments due by Period as of June 30, 2010  
            Less than                     After  
    Total     1 year     1-3 years     3-5 years     5 years  
Long-Term Debt Obligations
  $ 0     $ 0     $ 0     $ 0     $ 0  
Capital Lease Obligations
    0       0       0       0       0  
Operating Lease Obligations
    1,348       436       912       0       0  
Purchase Obligations
    1,727       1,727       0       0       0  
Other Long-Term Liabilities Reflected on the Company’s Balance Sheet under GAAP
    0       0       0       0       0  
 
                             
Total
  $ 3,075     $ 2,163     $ 912     $ 0     $ 0  
 
                             

24


Table of Contents

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
Forward Looking Statements
     This Report on Form 10-Q, including documents incorporated herein by reference, contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “believe,” “expect,” “estimate,” “anticipate,” “intend,” “may,” “might,” “will,” “would,” “could,” “project” and “predict,” or similar words and phrases generally identify forward-looking statements. Forward looking statements contained herein and in documents incorporated by reference herein include, but are not limited to statements regarding:
    our belief that we will not record additional recall charges;
 
    our belief that reserves for customer programs are adequate and proper;
 
    our expectation regarding continued expansion of the Zicam line of products;
 
    our expectation of achieving fiscal 2011 revenue in the $69.3 million to $70.7 million range;
 
    our expectation of achieving fiscal 2011 net income in the $2.0 million to $3.0 million range;
 
    our belief that our allowance for uncollectible accounts is adequate;
 
    our expectation that ongoing legal expense will be between $1.3 million and $1.8 million per quarter;
 
    our expectation that any federal consumer fraud and personal injury matter filed in the future will be transferred and consolidated pursuant to the MDL transfer process, subject to the plaintiff’s opportunity to object;
 
    our intention to vigorously defend the Zicam Cold Remedy product liability and securities litigation claims, our expectation that additional product liability lawsuits may be filed against us, and our belief that any liability resulting from these or other lawsuits, including any adverse publicity, could materially impact our financial results;
 
    our expectations regarding litigation reserves;
 
    our expectation of utilizing deferred tax assets;
 
    our expectation that sales in future periods will be affected by the recall of our nasal Cold Remedy products;
 
    our expectations regarding the effect of accounting standard updates;
 
    our expectation that retailers will add new or different Zicam products;
 
    our expectations regarding store brand competition;
 
    our intention to review our product return reserve provision regularly and adjust the reserve amounts if actual product returns differ materially from our reserve estimates;
 
    our expectation of making income tax payments at our statutory rates in future years;
 
    our expectation that operating expenses in fiscal 2011 will decline as a percentage of sales compared to fiscal 2010;

25


Table of Contents

    our expectation that the average unit cost of goods sold and gross margin will continue to be affected by the relative mix of products sold;
 
    our expectation that our net income and operating expenses in future periods will vary largely with the seasonality of our sales, the severity of the cold season, the revenues and expenses associated with new products, and the timing and amount of advertising, research and development, and legal expenses;
 
    our expectations regarding derivative instruments;
 
    our belief that we will not repurchase shares of common stock in the open market;
 
    our expectations regarding the amount of advertising expense and that advertising expense will be highest in our third and fourth fiscal quarters;
 
    our intention of focusing promotional and marketing support on Zicam oral Cold Remedy and nasal congestion products during the 2010/2011 cold season;
 
    our belief that focusing on consumer consumption of our oral Cold Remedy products will allow us to grow the Zicam brand;
 
    our belief that our existing capital resources are sufficient to fund our operations and capital requirements for the next 12 months;
 
    our expectations regarding our manufacturers’ ability to timely produce inventory adequate for sales of products through the 2010/2011 cough and cold season;
 
    our belief that moderate interest rate increases and current uncertainties regarding the availability of credit will not have a material adverse impact on our results of operations or financial position in the foreseeable future and that we are not subject in any material way to other forms of market risk.
     We may make additional written or oral forward-looking statements from time to time in filings with the Securities and Exchange Commission or in public news releases. Such additional statements may include, but not be limited to, projections of revenues, income or loss, capital expenditures, acquisitions, plans for future operations, financing needs or plans, the impact of inflation and plans relating to our products or services, as well as assumptions relating to the foregoing. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying our forward-looking statements.
     Statements in this Report on Form 10-Q, including those set forth in the sections entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and “Risk Factors,” describe factors that could contribute to or cause actual results to differ materially from our expectations. Other such factors include (i) the possibility that future sales of our products will not be as strong as expected; (ii) a weak cough and cold season; (iii) lack of market acceptance for or uncertainties concerning the efficacy or safety of our products; (iv) regulatory or enforcement actions, including product recalls, that could restrict our ability to market our products; (v) changing or modified regulatory or enforcement standards that could impact our ability to market our products; (vi) difficulties in manufacturers or suppliers meeting production requirements or maintaining sufficient inventories to meet unexpectedly high demand in the short term; (vii) financial difficulties encountered by one or more of our principal customers; (viii) increased competition from store brand versions of our products; (ix) material litigation involving, product liability claims, consumer issues, securities violation claims, or patent and contractual claims; (x) the possibility of delays or other difficulties in implementing product improvements and introducing to the marketplace new products; (xi) adverse publicity regarding our products or advertising restrictions; and (xii) adverse economic changes that affect consumer demand.
     Forward-looking statements contained in this Report on Form 10-Q speak only as of the date of this Report on Form 10-Q or, in the case of any document incorporated by reference, the date of that document.

26


Table of Contents

We do not undertake, and we specifically disclaim any obligation, to publicly update or revise any forward-looking statement contained in this Report on Form 10-Q or in any document incorporated herein by reference to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results over time.
Item 3. Quantitative and Qualitative Disclosures about Market Risk
     We believe that our existing capital resources will be sufficient to fund our operations and capital requirements for at least the next 12 months. We believe that interest rate increases and the current uncertainties regarding available credit will not have a material adverse impact on our results of operations or financial position in the foreseeable future.
     As of June 30, 2010 and March 31, 2010, we did not participate in any financial-market risk-sensitive commodity instruments for which fair value disclosure would be required. We believe that we are not subject in any material way to other forms of market risk, such as foreign currency exchange risk or foreign customer purchases or commodity price risk.
Item 4. Controls and Procedures
     We carried out an evaluation, under the supervision and with the participation of our President and Chief Executive Officer, of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rules 13a-15 and 15d-15 of the Securities Exchange Act of 1934. Based upon that evaluation, our President and Chief Executive Officer concluded that, as of the end of the period covered by this report, our disclosure controls and procedures were effective to ensure that information required to be disclosed in reports filed under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the required time periods and is accumulated and communicated to our management, including our President and Chief Executive Officer, as appropriate to allow timely decisions regarding required disclosure. There have been no changes in our internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) that occurred during the fiscal quarter ended June 30, 2010 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
PART II
OTHER INFORMATION
Item 1. Legal Proceedings
     See Note 7 — “Legal Proceedings” for a discussion of the principal legal proceedings to which the Company is a party.
Item 1A. Risk Factors
     In addition to the other information set forth in this report, you should carefully consider the risk factors disclosed in Part I, “Item 1A. Risk Factors” of our Annual Report on Form 10-K for the period ended March 31, 2010, each of which could materially affect the business, financial condition or future results of the Company. The risks described in such Form 10-K, and this Form 10-Q are not the only risks facing the Company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial in the future, also may materially adversely affect the business, financial condition and/or operating results of the Company.
Item 2. Unregistered Sales of Securities and Use of Proceeds
     The following table provides information about purchases by the Company during the quarter ended June 30, 2010 of equity securities that are registered by the Company pursuant to Section 12 of the Exchange Act.

27


Table of Contents

Issuer Purchases of Equity Securities
                         
                    Total Number of    
                    Shares Purchased as   Maximum Number of
    Total Number             Part of Publicly   Shares that May Yet be
    of Shares       Average Price     Announced Plans or   Purchased Under the
Period   Purchased(1)       Paid per Share     Programs   Plans or Programs
4/01/10-4/30/10
    8,531     $ 5.07     0   931,624
5/01/10-5/31/10
    22,673     $ 4.88     0   931,624
6/1/10-6/30/10
    0           0   931,624
 
                     
Total
    31,204     $ 4.93     0   931,624
 
(1)   The Company repurchased 31,204 shares of common stock, with an aggregate value of $153,820 from employees in satisfaction of their applicable tax withholding obligations on the vesting of restricted stock awards. Shares so surrendered are repurchased pursuant to the applicable award agreements and not pursuant to publicly-announced share repurchase programs.
     The Board of Directors of the Company approved a new stock repurchase program, effective January 26, 2009, which permits the Company to purchase up to 1.0 million shares of the Company’s common stock (the “2009 Program”). Concurrently with its approval of the 2009 Program, the Board of Directors terminated the repurchase program previously authorized in April 2004 (which authorized the repurchase of up to 1.0 million shares of the Company’s common stock). During the quarter ended June 30, 2010, we did not repurchase any shares of our common stock pursuant to the 2009 Program. The Company does not anticipate repurchasing shares of its common stock on the open market for the foreseeable future.
Item 6. Exhibits
     
Exhibit No.   Title
3.01
  Articles of Incorporation and Amendments thereto of the registrant (1)
 
   
3.02
  Bylaws of the registrant (2)
 
   
4.01
  Rights Agreement dated as of July 22, 2002 by and between the registrant and Corporate Stock Transfer, Inc. (3)
 
   
31.1*
  Certification of CEO and CFO pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
 
   
32.1*
  Certification of CEO and CFO pursuant to 18 U.S.C. Section 1350
 
  Filed with this Report on Form 10-Q.
 
**    Indicates management compensatory contract, plan or arrangement.
 
(1)   Incorporated by reference to the Registrant’s Amendment No. 1 to Form 8-A, filed June 18, 2002, file number 000-27646.
 
(2)   Incorporated by reference to the Registrant’s Report on Form 8-K, filed July 25, 2006, file number 001-31404.
 
(3)   Incorporated by reference to the Registrant’s Registration Statement on Form 8-A, filed July 23, 2002, file number 001-31404.

28


Table of Contents

SIGNATURES
     In accordance with the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
         
  Matrixx Initiatives, Inc.
 
 
  /s/ William J. Hemelt    
  William Hemelt   
Chief Executive Officer and
Principal Financial Officer
August 4, 2010 
 

29

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki